How has the COVID-19 pandemic impacted clinical trials?

How has the COVID-19 pandemic impacted clinical trials?

The study of multiple medical products is being affected by the COVID-19 outbreak. The FDA has stepped up and is instructing how to properly execute clinical trials during this ongoing pandemic.

One of the challenges medical professionals are facing is efficient quarantine. There has to be a safe environment for both the participants and the trial personnel.

The changes that are being implemented depend on the population of participants, location of trials, and medical products being used. An infection within the clinical trial will result in participants being removed from the study. 

Locations other than hospitals and labs may be used.

3 Key Points:

  1. Quarantine methods may make in-person visits unavailable.

      2. The outbreak of COVID-19 is limiting the availability of products being studied.

      3. The FDA aims to protect the integrity of clinical trials during the duration of the outbreak as well as the safety of participants.

Depending on the severity and duration of this pandemic, increasing difficulties may arise for conducting clinical trials. This is especially true for trials that are not directly related to Covid-19 prevention or treatment and trials that require in-person access to participants in hospitals and medical facilities.”  – GlobalData Healthcare, March 20, 2020

Artikel source:

#ClinicalTrials, #Healthcare, #Pharmaceutical

P.S. See Breaking News the impact of the COVID-19 pandemic on clinical trials! Get new Article Summaries delivered to your inbox, free. Click here to learn more.

Latest news

ACTide by Nubilaria against COVID-19

DECEIVER trial for COVID-19 related ARDS intensive care

Read more
Nubilaria for EUROLogin2020


Read more
Nubilaria ACTide @ SCOPE Virtual 2021

SCOPE – Summit for Clinical Ops Executives

Read more
Nubilaria Christmas wishes 2020

Merry Christmas and Happy new Year

Read more

Want more information about our solutions?
Contact us today.

I've read and accept theTerms and Conditions and the Privacy Policy
   I would like to receive information about products and services via traditional mail, telephone, email and automated communication systems